Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

NCT00604968 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Caelyx (pegylated liposomal doxorubicin; SCH 200746)

Sponsor

Merck Sharp & Dohme LLC